Luteinizing hormone β polymorphism and risk of familial and sporadic prostate cancer

David A. Elkins, Akira Yokomizo, Stephen N. Thibodeau, Daniel J. Schaid, Julie M. Cunningham, Angela Marks, Eric Christensen, Shannon K. McDonnell, Susan Slager, Brett J. Peterson, Steven J. Jacobsen, James R. Cerhan, Michael L. Blute, Donald J. Tindall, Wanguo Liu

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


BACKGROUND. Circulating testosterone plays an important role in maintenance and growth of prostate cells. Luteinizing hormone (LH), secreted from the anterior pituitary, signals testicular Leydig cells to secrete testosterone. A genetic variant of the LH-β protein, LH-βV, exists in up to 40% of Caucasians and is more bioactive than the wild-type protein. We hypothesized that genetically determined variation in LH function might affect susceptibility to prostate cancer via altered testosterone secretion. METHODS. We determined the frequency of the LH-βV polymorphism (two linked polymorphisms: Trp8 → Arg and Ile15 → Thr) in familial prostate cancer patients (n = 446), in sporadic prostate cancer patients (n = 388), and in population-based controls without prostate cancer (n = 510) to assess the role of this polymorphism in susceptibility to rostate cancer. RESULTS. A higher frequency of this variant genotype (LH-βV: Arg8/Thr15) was observed in familial prostate cancer patients (18.6%) than in controls (13.7%), and after taking into account the correlation of the familial cases and adjusting for age and body mass index (BMI), there was a weak positive association between the variant LH-β genotype, and risk of familial prostate cancer (OR = 1.29; 95% CI 0.96-1.75). The sporadic case group was also slightly more likely to have a variant genotype (15.2%) compared to the controls (13.7%), and after adjustment for age and BMI, a similar association with this variant was found (OR = 1.33; 95% CI 0.86-02.07). Surgical cases showed a slightly stronger association for the variant LH-β genotype compared to non-surgical cases, but among the surgical cases there was little variability in risk across nodal status, stage, and tumor grade. CONCLUSIONS. These data are consistent with the hypothesis that the LH-β variant is a weak risk factor for prostate cancer.

Original languageEnglish (US)
Pages (from-to)30-36
Number of pages7
Issue number1
StatePublished - Jun 15 2003


  • Luteinizing hormone
  • Polymorphism
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Luteinizing hormone β polymorphism and risk of familial and sporadic prostate cancer'. Together they form a unique fingerprint.

Cite this